BUFFALO, NY--(Marketwire - November 26, 2007) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the initiation of its Phase II efficacy study for Curaxin CBLC102 in advanced renal cell carcinoma (a highly fatal form of kidney cancer) at ClinWorks Cancer Research Center in Charlotte, NC.
